In the U.S., a third of Americans are at risk of chronic kidney disease, and age is a major factor. More than half of Americans over 75 are thought to have some sort of kidney damage. Here's what... -- Read more on ScientificAmerican.com
The job of the oncologist of the future will be to prevent and treat the emergence of disease -- Read more on ScientificAmerican.com
The job of the oncologist of the future will be to prevent and treat the emergence of disease -- Read more on ScientificAmerican.com
Social science offers valuable lessons about ways to convince those who are hesitant about the shots -- Read more on ScientificAmerican.com
Companies are scrambling to obtain supplies for hundreds of millions of doses of a type of vaccine that has never been made at this scale before -- Read more on ScientificAmerican.com
Companies are scrambling to obtain supplies for hundreds of millions of doses of a type of vaccine that has never been made at this scale before -- Read more on ScientificAmerican.com
Companies are scrambling to obtain supplies for hundreds of millions of doses of a type of vaccine that has never been made at this scale before -- Read more on ScientificAmerican.com
There is evidence the new variant could be more transmissible, yet vaccines work very well against it -- Read more on ScientificAmerican.com
Two RNA vaccines will be useful as U.S. infections surge, but the speedy authorizations complicate clinical trials -- Read more on ScientificAmerican.com
Kidney disease affects millions of Americans, but corporate capture of dialysis, along with disparities in treatment and transplant access, mean that not everyone's journey is the same. -- Read more on ScientificAmerican.com
Treatments that reduce suffering and incorporate patient values aren’t common in kidney disease care. That’s changing. -- Read more on ScientificAmerican.com
Demand for healthy kidneys has long outstripped supply. But better testing and treatment is expanding the donor pool. -- Read more on ScientificAmerican.com
Minority patients are diagnosed later, stay on dialysis longer, and are added to transplant lists less quickly. Why? -- Read more on ScientificAmerican.com
Joint ventures between nephrologists and dialysis centers have expanded treatment. Critics ask: At what cost? -- Read more on ScientificAmerican.com
Kidney disease affects millions of Americans, but corporate capture of dialysis, along with disparities in treatment and transplant access, mean that not everyone's journey is the same. On this... -- Read more on ScientificAmerican.com
Kidney disease affects millions of Americans, but corporate capture of dialysis, along with disparities in treatment and transplant access, mean that not everyone's journey is the same. On this... -- Read more on ScientificAmerican.com